AS-172: Long-Term Follow-Up Results According to Therapeutic Modalities for the Stent Fracture in Patients with Sirolimus-Eluting Stent Implantation

2009 ◽  
Vol 103 (9) ◽  
pp. 75B
Author(s):  
Tae-Hyun Yang ◽  
Doo-Il Kim ◽  
Ki-Hun Kim ◽  
Yang-Chun Han ◽  
Sang-Hoon Seol ◽  
...  
2020 ◽  
Vol 84 (7) ◽  
pp. 1196
Author(s):  
Toru Yoshizaki ◽  
Aki Kobayashi ◽  
Takamitsu Nakamura ◽  
Jun-ei Obata ◽  
Kiyotaka Kugiyama

2008 ◽  
Vol 51 (9) ◽  
pp. 968-969 ◽  
Author(s):  
Masamichi Takano ◽  
Masanori Yamamoto ◽  
Shigenobu Inami ◽  
Daisuke Murakami ◽  
Koji Seimiya ◽  
...  

2012 ◽  
Vol 101 (9) ◽  
pp. 709-716 ◽  
Author(s):  
Ralf Zahn ◽  
Franz-Josef Neumann ◽  
Heinz-Joachim Büttner ◽  
Gert Richardt ◽  
Steffen Schneider ◽  
...  

2018 ◽  
Vol 72 (13) ◽  
pp. B305
Author(s):  
Daisuke Hahcinohe ◽  
Azeem Latib ◽  
Alessandra Laricchia ◽  
Gianmarco Iannopollo ◽  
Ozan Demir ◽  
...  

2019 ◽  
Vol 15 (4) ◽  
pp. 295-300 ◽  
Author(s):  
Ofer Kobo ◽  
Ariel Roguin

Recent stent developments aimed to reduce and eliminate the long-term inflammatory response include thinner struts, modifications to stent design and the development of bioresorbable polymers (BP). We aimed to summarize the main findings and to discuss the established and the potential benefits of the Orsiro BP sirolimus-eluting stents in everyday clinical use. We have reviewed the available evidence on the clinical performance of the Orsiro BP drug-eluting stents. Orsiro BP sirolimus-eluting stents is clinically proven and showed noninferiority against major drug-eluting stents and provides high safety and efficacy profile at long-term follow-up. Furthermore, it may be the preferred treatment option in specific subgroups as acute coronary syndrome, as shown in the BIOFLOW V trial.


Sign in / Sign up

Export Citation Format

Share Document